title: Bilateral, multiple, episodic retinal vein occlusions associated with common variable immunodeficiency.
authors.affiliation: Retina Division, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.
authors.forename: Ian C
authors.initials: IC
authors.lastname: Han
authors.affiliation: Retina Associates of Cleveland, Cleveland, Ohio.
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Singerman
authors.affiliation: Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio.
authors.forename: Alvin
authors.initials: A
authors.lastname: Schmaier
authors.affiliation: Retina Division, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland4Editor, JAMA Ophthalmology.
authors.forename: Neil M
authors.initials: NM
authors.lastname: Bressler
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D002648:Child; D017074:Common Variable Immunodeficiency / Q000150:complications*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology; D015861:Retinal Neovascularization / Q000209:etiology / Q000601:surgery; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D007075:Immunoglobulin M; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab